These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 38056198)
21. Treatment of rituximab in patients with idiopathic membranous nephropathy: a case series and literature review. Jeon SJ; Kim JH; Noh HW; Lee GY; Lim JH; Jung HY; Cho JH; Choi JY; Kim CD; Kim YL; Park SH Korean J Intern Med; 2022 Jul; 37(4):830-840. PubMed ID: 35421909 [TBL] [Abstract][Full Text] [Related]
22. Successful Treatment of Patients With Refractory PLA Klomjit N; Fervenza FC; Zand L Am J Kidney Dis; 2020 Dec; 76(6):883-888. PubMed ID: 32311405 [TBL] [Abstract][Full Text] [Related]
23. Clinical features, course and prognosis of idiopathic membranous nephropathy depending on the presence of antibodies against M-type phospholipase A2 receptor. Jatem Escalante E; Segarra Medrano A; Carnicer Cáceres C; Martín-Gómez MA; Salcedo Allende MT; Ostos Roldan H; Agraz Pamplona I Nefrologia; 2015; 35(5):479-86. PubMed ID: 26306972 [TBL] [Abstract][Full Text] [Related]
24. Prognostic value of PLA2R autoimmunity detected by measurement of anti-PLA2R antibodies combined with detection of PLA2R antigen in membranous nephropathy: A single-centre study over 14 years. Pourcine F; Dahan K; Mihout F; Cachanado M; Brocheriou I; Debiec H; Ronco P PLoS One; 2017; 12(3):e0173201. PubMed ID: 28257452 [TBL] [Abstract][Full Text] [Related]
25. Ofatumumab in Rituximab-Resistant and Rituximab-Intolerant Patients With Primary Membranous Nephropathy: A Case Series. Podestà MA; Trillini M; Portalupi V; Gennarini A; Tomatis F; Villa A; Perna A; Rubis N; Remuzzi G; Ruggenenti P Am J Kidney Dis; 2024 Mar; 83(3):340-349.e1. PubMed ID: 37777061 [TBL] [Abstract][Full Text] [Related]
26. Recurrent Membranous Nephropathy After Kidney Transplantation Associated With Phospholipase A2 Receptor and Successfully Treated With Rituximab: A Case Report. Ishiwatari A; Wakai S; Shirakawa H; Honda K Transplant Proc; 2018 Oct; 50(8):2565-2568. PubMed ID: 30316399 [TBL] [Abstract][Full Text] [Related]
27. [A novel approach to rapid induction of remission in primary membranous nephropathy]. Dobronravov VA; Bystrova OB; Kochoyan ZS; Fomicheva EN Ter Arkh; 2021 Jun; 93(6):706-712. PubMed ID: 36286838 [TBL] [Abstract][Full Text] [Related]
28. [Membranous nephropathy: New insights in therapeutic approach]. Dahan K Nephrol Ther; 2017 Apr; 13 Suppl 1():S83-S87. PubMed ID: 28577748 [TBL] [Abstract][Full Text] [Related]
29. Diagnostic specificity of autoantibodies to M-type phospholipase A2 receptor (PLA2R) in differentiating idiopathic membranous nephropathy (IMN) from secondary forms and other glomerular diseases. Radice A; Pieruzzi F; Trezzi B; Ghiggeri G; Napodano P; D'Amico M; Stellato T; Brugnano R; Ravera F; Rolla D; Pesce G; Giovenzana ME; Londrino F; Cantaluppi V; Pregnolato F; Volpi A; Rombolà G; Moroni G; Ortisi G; Sinico RA J Nephrol; 2018 Apr; 31(2):271-278. PubMed ID: 29081027 [TBL] [Abstract][Full Text] [Related]
30. [Clinical Significance of IgG4 Level in Predicting the Activity and Outcome of Phospholipase A2 Receptor-associated Membranous Nephropathy]. DU YY; Jiang X; Wang WR; Tang XL; Sun Y Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2022 Aug; 44(4):579-584. PubMed ID: 36065689 [TBL] [Abstract][Full Text] [Related]
31. Rituximab in Patients With Phospholipase A2 Receptor-Associated Membranous Nephropathy and Severe CKD. Hanset N; Esteve E; Plaisier E; Johanet C; Michel PA; Boffa JJ; Fievet P; Mesnard L; Morelle J; Ronco P; Dahan K Kidney Int Rep; 2020 Mar; 5(3):331-338. PubMed ID: 32154454 [TBL] [Abstract][Full Text] [Related]
32. Analysis of predictive factors for immunosuppressive response in anti-phospholipase A2 receptor antibody positive membranous nephropathy. Li C; Li H; Wen YB; Li XM; Li XW BMC Nephrol; 2018 Dec; 19(1):354. PubMed ID: 30541581 [TBL] [Abstract][Full Text] [Related]
33. Anti-Phospholipase A2 Receptor (Anti-PLA2R) Antibody in Diagnosis and Treatment of Idiopathic Membranous Nephropathy: A Single-Center Observational Study in China. Guo N; Cao Y; Dai H; Yuan L; Shi L; Zhang Y Med Sci Monit; 2019 Dec; 25():9364-9368. PubMed ID: 31813930 [TBL] [Abstract][Full Text] [Related]
34. Anti-phospholipase A2 receptor antibody levels at diagnosis predicts outcome of TAC-based treatment for idiopathic membranous nephropathy patients. Wang B; Zhu Z; Huang F; Huang H; Tu L; Wang Y; Zheng L; Zhou J; Wei X BMC Nephrol; 2022 Sep; 23(1):306. PubMed ID: 36068486 [TBL] [Abstract][Full Text] [Related]
35. Primary membranous nephropathy in children and adolescents: a single-centre report from South Asia. Ramachandran R; Nayak S; Kumar V; Kumar A; Agrawal N; Bansal R; Tiewsoh K; Nada R; Rathi M; Kohli HS Pediatr Nephrol; 2021 May; 36(5):1217-1226. PubMed ID: 33108509 [TBL] [Abstract][Full Text] [Related]
37. A case report of breast cancer and membranous nephropathy with positive anti phospholipase A2 receptor antibodies. Mathew D; Gupta S; Ashman N BMC Nephrol; 2021 Sep; 22(1):324. PubMed ID: 34592934 [TBL] [Abstract][Full Text] [Related]
38. Primary membranous glomerulonephritis with negative serum PLA2R in haemophilia A successfully managed with rituximab - case report and review of the literature. Meyer N; Cooper W; Kirwan P; Garsia R; Dunkley S; Gracey DM BMC Nephrol; 2021 Jul; 22(1):268. PubMed ID: 34294065 [TBL] [Abstract][Full Text] [Related]
39. Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN). Radice A; Trezzi B; Maggiore U; Pregnolato F; Stellato T; Napodano P; Rolla D; Pesce G; D'Amico M; Santoro D; Londrino F; Ravera F; Ortisi G; Sinico RA Autoimmun Rev; 2016 Feb; 15(2):146-54. PubMed ID: 26527329 [TBL] [Abstract][Full Text] [Related]
40. The application of podocyte antigen PLA2R and anti-PLA2R antibody in the diagnosis and treatment of membranous nephropathy. Chen Y; Xu Y; Chen S; Yu Y; Zhu X; Chen J Ren Fail; 2023; 45(2):2264939. PubMed ID: 37814415 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]